Low molecular weight heparin for the prevention of veno-occlusive disease of the liver in bone marrow transplantation patients

Transplantation

Volumn 61, Issue 7, 1996, Pages 1067-1071

  Or, Reuven ^a   Nagler, Arnon ^a   Shpilberg, Ofer ^b   Elad, Sharon ^a   Naparstek, Ella ^a   Kapelushnik, Joseph ^a   Cass, Yacov ^a   Gillis, Samuel ^a   Chetrit, Angela ^b   Slavin, Shimon ^a   Eldor, Amiram ^c,d  

^a HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

^b SHEBA MEDICAL CENTER   (Israel)

^c TEL AVIV SOURASKY MEDICAL CENTER   (Israel)

^d TEL AVIV UNIVERSITY   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

BILIRUBIN; BUSULFAN; CARBOPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; ENOXAPARIN; ETOPOSIDE; LOW MOLECULAR WEIGHT HEPARIN; MELPHALAN; MITOXANTRONE; PLACEBO; THIOTEPA;

ADULT; ARTICLE; BLEEDING; BONE MARROW TRANSPLANTATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; FEMALE; HEPATOMEGALY; HUMAN; LIVER VEIN OBSTRUCTION; LYMPH NODE IRRADIATION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SUBCUTANEOUS DRUG ADMINISTRATION; THROMBOCYTE TRANSFUSION; THROMBOCYTOPENIA; WHOLE BODY RADIATION;

ADULT; BLOOD PLATELETS; BONE MARROW TRANSPLANTATION; FEMALE; FIBRINOLYTIC AGENTS; HEPARIN, LOW-MOLECULAR-WEIGHT; HEPATIC VENO-OCCLUSIVE DISEASE; HUMANS; MALE; MIDDLE AGED;

EID: 9244265492     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007890-199604150-00014     Document Type: Article

References (34)

1. Shulman HM, Hinterberger W. Hepatic veno-occlusive disease - liver toxicity syndrome after bone marrow transplantation. Bone Marrow Transplant 1992; 10: 197.
2. Rollins BJ. Hepatic veno-occlusive disease. Am J Med 1986; 81: 297.
3. Berk PD, Popper H, Krueger GR, Decter J, Herzig G, Graw RG. Veno-occlusive disease of the liver after allogeneic bone marrow transplantation. Ann Intern Med 1979; 90: 158.
4. Jones RJ, Lee KS, Beschorner WE, et al. Veno-occlusive disease of the liver following bone marrow transplantation. Transplantation 1987; 44: 778.
5. Brodsky R, Topolsky D, Crilley P, Bulova S, Brodsky J. Frequency of veno-occlusive disease of the liver in bone marrow transplantation with a modified busulfan/cyclophosphamide preparative regimen. Am J Clin Oncol 1990; 13: 221.
6. Soiffer RJ, Dear K, Rabinowe SN, et al. Hepatic dysfunction following T-cell depleted allogeneic bone marrow transplantation. Transplantation 1991; 52: 1014.
7. Stern DM, Carpenter B, Nawroth PP. Endothelium and regulation of coagulation. Pathol Immunopathol Res 1086; 5: 29.
8. Nawroth PP, Stern DM. Modulation of endothelial cell hemostatic properties by tumor necrosis factor. J Exp Med 1986; 163: 740.
9. Shulman HN, Gown AM, Nugent DJ. Hepatic veno-occlusive disease after bone marrow transplantation: immunohistochemical identification of the material within occluded central venules. Am J Pathol 1987; 127: 549.
10. Cahn JY, Flesch M, Plouvier E, Herve P, Rosenbaum A. Maladie veino-occlusive fue foie, et autografe de moelle osseuse: role preventif de l'heparin? Nouv Rev Fr Hematol 1985; 27: 27.
11. Rio BY, Lamy T, Zittoun R. Preventive role of heparin for liver veno-occlusive disease (VOD). Bone Marrow Transplant 1988; 3: 266.
12. Bearman SI, Hind MS, Wolford JL, et al. A pilot study of continuous infusion heparin for prevention of hepatic veno-occlusive disease after bone marrow transplantation. Bone Marrow Transplant 1990; 5: 407.
13. Attal M, Huguet F, Rubie H, et al. Prevention of hepatic veno-occlusive disease after bone marrow transplantation: a prospective, randomized trial. Blood 1992; 79: 2834.
14. Hirsh J, Levine N. Low molecular weight heparin. Blood 1992; 79: 1.
15. Buckley MM, Sorkin EM. Enoxaparin: a review of its pharmacology and clinical application in the prevention and treatment of thromboembolic disorders. Drugs Reprint 1992; 4: 465.
16. Hoek JA, Nurmohamed MT, Hamelynck KJ, et al. Prevention of deep vein thrombosis following total hip replacement by a low molecular weight heparinoid. Thromb Hemostas 1989; 67: 28.
17. Mohr VD, Lentz J. Heparin assozierte Thrombose und Embolie. Unerwuenschte Wirkung der thromboembolie Prophylaxe mit dem nieder molekularen Heparin enoxaparin? Chirurgie 1991; 62: 686.
18. Kakkar V, Murray WJ. Efficacy and safety of low molecular weight heparin (CY216) in preventing post operative venous thromboembolism. Br J Surg 1985; 72: 786.
19. Prandoni P, Lensing AW, Buller HR, et al. Comparison of subcutaneous low molecular weight with intravenous standard heparin in proximal deep vein thrombosis. Lancet 1992; 339: 441.
20. Hull RD, Raskob MS, Pineo GF, et al. Subcutaneous low molecular weight heparin compared with continuous intravenous heparin in the treatment of proximal vein thrombosis. N Engl J Med 1992; 326: 975.
21. Simonneau G, Charbonnier B, Decousus H, et al. Subcutaneous fixed dose of enoxaparin versus intravenous adjusted dose of unfractionated heparin in the treatment of deep vein thrombosis. Arch Intern Med 1993; 153: 1541.
22. Drakos PE, Nagler A, Or R, Gillis S, Slavin S, Eldor A. Low molecular weight heparin for Hickman catheter induced thrombosis in thrombocytopenic patients undergoing bone marrow transplantation. Cancer 1992; 70: 1895.
23. McDonald GB, Sharma P, Matthews DE, Shulman HM, Thomas ED. Veno-occlusive disease of the liver after bone marrow transplantation: diagnosis, incidence and predisposing factors. Hepatology 1984; 4: 116.
24. Faioni EM, Bearman SI, Krachmainicoff A, et al. Procoagulant imbalance due to low levels of protein C in patients with veno-occlusive disease (VOD) of the liver after marrow transplantation. Blood 1991; 78: 762.
25. Bara L, Billaud E, Gramond G, Kher A, Samama M. Comparative pharmacokinetics of low molecular weight heparin (PK 19169) and unfractionated heparin after intravenous and subcutaneous administration. Thromb Res 1985; 39: 631.
26. Bara L, Samama M. Pharmacokinetics of low molecular weight heparins. Acta Chir Scand 1988; 556: 57.
27. Bradbrook ID, Magnani HN, Moelker C, et al. A low molecular weight heparinoid anticoagulant with a long half life in man. Br J Clin Parmacol 1987; 23: 667.
28. Handeland GF, Abildgaard H, Holm HA, Arnesen KE. Dose adjusted heparin treatment of deep venous thrombosis: a comparison of unfractionated and low molecular weight heparin. Eur J Clin Pharmacol 1990; 39: 107.
29. Gillis S, Eldor A. Heparin-induced thrombocytopenia - pathogenesis and treatment. Isr J Med Sci 1993; 29: 473.
30. Chong BH, Ismail F, Cade J, Gallus AS, Gordon S, Chesterman CN. Heparin-induced thrombocytopenia: studies with a low molecular weight heparinoid. Blood 1989; 73: 1592.
31. Shen ZX, Basara N, Xi XD, et al. Fraxaparin, a low molecular weight heparin, stimulated megakaryocytopoiesis in vitro and in vivo in mice. Br J Haematol 1994; 88: 602.
32. Kaushansky K, Lok S, Holly RD, et al. Promotion of megakaryocyte progenitor expansion and differentiation by the c-Mpl ligand thrombopoietin. Nature 1994; 369: 568.
33. Han ZC, Wan HY, Bellucci S, et al. Glycosaminoglycans stimulate megakaryocytopoiesis in vitro and in vivo. Exp Hematol 1993; 21: 1016.
34. Spiro TE, Johnson GJ, Christie MJ, et al. Efficacy and safety of enoxaparin to prevent deep venous thrombosis after hip replacement surgery. Ann Intern Med 1994; 121: 81.